149 research outputs found
On a mathematical model of morphogenesis
We consider a simple mathematical model of distribution of morphogens (signaling molecules responsible for the differentiation of cells and the creation of tissue patterns) similar to the model proposed by Lander, Nie and Wan in 2002.The model consists of a system of two equations: a PDE of parabolic type modeling the distribution of free morphogens with a dynamic boundary condition and an ODE describing the evolution of bound receptors. Three biological processes are taken into account: diffusion, degradation and reversible binding. We prove existence and uniqueness of solutions and its asymptotic behavior
On the Keller-Segel System with External Application of Chemoattractant
Chemotaxis is the ability of microorganisms to respond to chemical signals by moving along the gradient of the chemical substance, either toward the higher concentration (positive taxis) or away from it (negative taxis)
Inverse Problems in Lubrication Theory
Lubrication is the process whereby a fluid (the lubricant) fills the gap between two surfaces in close proximity and relative motion. Lubrication is employed to reduce friction and avoid contac
Complex Ginzburg-Landau equations with a delayed nonlocal perturbation
Depto. de Análisis Matemático y Matemática AplicadaFac. de Ciencias MatemáticasTRUEpu
An inverse problem for the compressible Reynolds equation
We study the existence of solutions to a system of equations for equilibrium positions in lubricated journal bearings under load effects. The mechanism under consideration consists of two parallel cylinders, one inside the other, in close distance and relative motion. The unknowns of the problem are the equilibrium position of the inner cylinder and the pressure of the lubricant described by the compressible Reynolds equation. To complete the system, Newton's second law gives the equilibrium of forces. We present results on existence of solutions for a range of applied forces F
Mathematical Analysis and Numerical Simulation in Magnetic Recording
The head-tape interaction in magnetic recording is described in the literature by a coupled system of partial differential equations. In this paper we study the limit case of the system which reduces the problem to a second order nonlocal equation on a one-dimensional domain. We describe the numerical method of resolution of the problem, which is reformulated as an obstacle one to prevent head-tape contact. A finite element method and a duality algorithm handling Yosida approximation tools for maximal monotone operators are used in order to solve numerically the obstacle problem. Numerical simulations are introduced to describe some qualitative properties of the solution. Finally some conclusions are drawn
Effect of sex in systemic psoriasis therapy: Differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be pre-scribed biologics. There were no differences between men and women in effectiveness of therapy, measur-ed in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de DermatologÃa y VenereologÃa, which receives financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios) and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, Janssen and Almirall)
Assessment of platelet REACtivity after transcatheter aortic valve replacement
OBJECTIVES:
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.
BACKGROUND:
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.
METHODS:
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.
RESULTS:
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.
CONCLUSIONS:
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066)
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial
OBJECTIVES: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI. BACKGROUND: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence. METHODS: This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR. RESULTS: A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR. CONCLUSIONS: HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066)
- …